Catalyst Pharmaceutical Partners
Commercial-stage biopharma Catalyst Pharmaceuticals targets the U.S. rare‑disease market with a portfolio of four branded drugs—Firdapse (LEMS), Fycompa (seizures), Ruzurgi (pediatric LEMS), and AGAMREE (Duchenne)—backed by license deals with BioMarin and Endo Ventures.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 181
- HQ: Coral Gables
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.